Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
Medtronic Cardiac Rhythm Disease Management · Decision date Sep 25, 2026
What did the FDA decide?
This 30-day notice records updates to visual inspection criteria for anode components at the Medtronic Energy and Component Center (MECC). The change applies to the Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, and Crome MRI CRT-D devices under PMA P010031, supplement S932.
The supplement is categorized as a process change involving the manufacturer, sterilizer, packager, or supplier. The FDA decision field shows OK30. The statement does not describe what specific inspection criteria changed, what prompted the update, or any effect on device performance or safety.
FDA approval order statement
updates to visual inspection criteria for anode components at the Medtronic Energy and Component Center (MECC)
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 25, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P010031/S932
- Regulatory pathway
- PMA supplement
- Product code
- NIK
- Decision code
- OK30
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).
- Product code
- NIK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010031 · Original PMA
CONCERTO/INSYNC SENTRY/INSYNC MAXIMO IMPLANTABLE CARDIOVASCULAR DEFIBRILLATORS WITH CARDIAC RESYNCHICNIZATION
P010031/S932 received
Application receipt date recorded by FDA.
P010031/S932 · FDA decision
30-Day Notice
P010031/S933 · Related supplement
Cobalt MRI CRT-D (DTPB2Dl, DTPB2D4, DTPB2Ql, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2Dl, DTPA2D4, DTPA2Ql, DTPA2QQ); Crome M
P010031/S934 · Related supplement
Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
P010031/S931 · Related supplement
Cobalt MRI CRT-D (DTPB2D1, DTPB2D4, DTPB2Q1, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2D1, DTPA2D4, DTPA2Q1, DTPA2QQ); Crome M
Timeline entries are records held by MedtechLedger for P010031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Cardiac Rhythm Disease Management | PMA approval | Jun 26, 2002 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Cardiac Rhythm Disease Management
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010031/S932
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


